Net Present Value Model: Nuvaxovid
Powered by
Unlock hidden opportunities in the NPV industry
Overview
Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis.
Drug Operating Profit Model
Nuvaxovid Drug Details
Coronavirus Disease 2019 vaccine (Covovax, Nuvaxovid) consists of recombinant Spike Protein of SARS-CoV-2 Virus acts as immunizing agent. Covovax is a recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M adjuvant. It is formulated as suspension and solution for intramuscular route of administration. Covovax is indicated for active immunization of individuals 18 years of age for prevention coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2. Nuvaxovid is indicated for the active immunization to prevent Covid-19 caused by SARS-CoV-2 in individuals 18 years of age and older. Nuvaxovid is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age through 17. Covovax is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 7 years of age and older. COVID-19 Vaccine is indicated for the prevention of Coronavirus Disease 2019 (COVID-19) for individuals 18 years of age and older.NVX-CoV2373 is under development for the prevention of coronavirus disease 2019 (COVID-19). The vaccine candidate comprises of antigens derived from the coronavirus spike (S) protein. It is being developed based on recombinant protein nanoparticle technology. The company expects to utilize its proprietary Matrix-M adjuvant with its COVID-19 vaccine candidate to enhance immune responses. It is administered through intramuscular route.
Report Coverage
GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
Quick View – NPV Data | |||
Drug Name |
|
||
Administration Pathway |
|
||
Therapeutic Areas | |||
Key Manufacturers |
|
||
Drug Development Status |
|
Reasons to Buy
- Better understand the quantitative value of a specific drug
- Create or support internal NPV models to improve accuracy
- Understand the profit a drug is expected to make, taking into account revenue and cost forecasts leveraging public and proprietary data sets.
Frequently asked questions
- All drug sales and forecasts within NPV Model are calculated in our proprietary company based models . In these models, Analyst Consensus forecasts are built by using company-specific broker reports to create the sales forecasts for each Drug and Segment.
- Sales and forecasts are not indication-specific where drugs are approved , or in development, for multiple indications. Please refer to GlobalData’s Disease Analysis reports for indication-specific sales forecasts.
- Risk-adjusted NPVs use GlobalData’s LoA and PTSR for the indication in the highest development stage. Please refer to the Likelihood of Approval methodology for more details on this content.
GlobalData’s NPV Model is a premium model providing a fully-interactive forecasting and valuation tool, driven by Analyst Consensus estimates, enabling users to analyze and customize valuations for pharmaceutical assets including drugs or segments. The tool provides 17-year drug forecasts from companies with sales forecast data in the pharmaceutical industry, including established global firms and emerging biotechs, which allows access to critical information to facilitate strategic decision making around pharmaceutical assets
The NPV Model includes a forecasted Revenue Model, followed by a proprietary Patent Expiry Model, Operating Profit Model, Net Profit (apply Tax rate) and Discounted Cash Flow (apply Discount rates), to derive Net Present Value (NPV) for a chosen pharmaceutical asset
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.